Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Autoimmune Disorders

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 97 articles:
HTML format



Single Articles


    June 2022
  1. MAGLIOZZI R, Fadda G, Brown RA, Bar-Or A, et al
    "Ependymal-in" gradient of thalamic damage in progressive multiple sclerosis.
    Ann Neurol. 2022 Jun 24. doi: 10.1002/ana.26448.
    PubMed     Abstract available


  2. RAHMANZADEH R, Galbusera R, Lu PJ, Bahn E, et al
    A new advanced MRI biomarker for remyelinated lesions in Multiple Sclerosis.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26441.
    PubMed     Abstract available


  3. KOIZUMI N, Takasugi J, Ohara N, Kawamoto M, et al
    FDG-PET/CT of Giant Cell Arteritis With Normal Inflammatory Markers.
    Ann Neurol. 2022 Jun 6. doi: 10.1002/ana.26428.
    PubMed    


  4. OECHTERING J, Lincke T, Schaedelin S, Decard BF, et al
    Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
    Ann Neurol. 2022;91:814-820.
    PubMed     Abstract available


    May 2022
  5. ZEYDAN B, Rocca MA, Kantarci OH, Filippi M, et al
    Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS.
    Ann Neurol. 2022;91:734-735.
    PubMed    


  6. GHIROTTO B, Oliveira DF, Cipelli M, Basso PJ, et al
    MS-Driven Metabolic Alterations Are Recapitulated in iPSC-Derived Astrocytes.
    Ann Neurol. 2022;91:652-669.
    PubMed     Abstract available


  7. DIEBOLD M, Galli E, Kopf A, Sanderson N, et al
    Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
    Ann Neurol. 2022;91:676-681.
    PubMed     Abstract available


    April 2022
  8. MANDEL-BREHM C, Benson LA, Tran B, Kung AF, et al
    ZSCAN1 autoantibodies are associated with pediatric paraneoplastic ROHHAD.
    Ann Neurol. 2022 Apr 25. doi: 10.1002/ana.26380.
    PubMed     Abstract available


  9. BOSE G, Healy BC, Lokhande HA, Sotiropoulos MG, et al
    Early predictors of clinical and MRI outcomes using LASSO in multiple sclerosis.
    Ann Neurol. 2022 Apr 15. doi: 10.1002/ana.26370.
    PubMed     Abstract available


  10. IWAMOTO S, Itokazu T, Sasaki A, Kataoka H, et al
    RGMa Signal in Macrophages Induces Neutrophil-Related Astrocytopathy in NMO.
    Ann Neurol. 2022;91:532-547.
    PubMed     Abstract available


  11. DOETS AY, Walgaard C, Lingsma HF, Islam B, et al
    International Validation of the Erasmus Guillain-Barre Syndrome Respiratory Insufficiency Score.
    Ann Neurol. 2022;91:521-531.
    PubMed     Abstract available


    March 2022
  12. KISTER I, Patskovsky Y, Curtin R, Pei J, et al
    Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study.
    Ann Neurol. 2022 Mar 15. doi: 10.1002/ana.26346.
    PubMed     Abstract available


  13. LANGER-GOULD A, Cheng SC, Li BH, Smith JB, et al
    Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26352.
    PubMed     Abstract available


  14. BRILL L, Raposo C, Rechtman A, Zveik O, et al
    SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab.
    Ann Neurol. 2022 Mar 4. doi: 10.1002/ana.26343.
    PubMed     Abstract available


  15. KORNEK B, Leutmezer F, Rommer PS, Koblischke M, et al
    B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients.
    Ann Neurol. 2022;91:342-352.
    PubMed     Abstract available


    February 2022
  16. DE MEO E, Filippi M, Trojano M, Comi G, et al
    Comparing natural history of early and late onset pediatric multiple sclerosis.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26322.
    PubMed     Abstract available


  17. ZEKERIDOU A, Yang B, Lennon VA, Guo Y, et al
    Anti-Neuronal Nuclear Antibody 3 Autoimmunity targets Dachshund homolog 1.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26320.
    PubMed     Abstract available


  18. MCCOMBE JA, Flanagan EP, Chen JJ, Zekeridou A, et al
    Investigating the Immunopathogenic Mechanisms Underlying MOGAD.
    Ann Neurol. 2022;91:299-300.
    PubMed    


    January 2022
  19. MCKAY KA, Bedri SK, Manouchehrinia A, Stawiarz L, et al
    Reduction in cognitive processing speed surrounding multiple sclerosis relapse.
    Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26301.
    PubMed     Abstract available


    December 2021
  20. FLEISCHER V, Ciolac D, Gonzalez-Escamilla G, Grothe M, et al
    Subcortical volumes as early predictors of fatigue in multiple sclerosis.
    Ann Neurol. 2021 Dec 30. doi: 10.1002/ana.26290.
    PubMed     Abstract available


  21. BISCHOF A, Papinutto N, Keshavan A, Rajesh A, et al
    Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis.
    Ann Neurol. 2021 Dec 8. doi: 10.1002/ana.26281.
    PubMed     Abstract available


  22. HEINE J, Kopp UA, Klag J, Ploner CJ, et al
    Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.
    Ann Neurol. 2021;90:949-961.
    PubMed     Abstract available


  23. SANTYR B, Pejhan S, Zhang Q, Budhram A, et al
    Unilateral Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2021;90:999-1000.
    PubMed    


    November 2021
  24. ZRZAVY T, Endmayr V, Bauer J, Macher S, et al
    Neuropathological Variability within a Spectrum of NMDAR-Encephalitis.
    Ann Neurol. 2021;90:725-737.
    PubMed     Abstract available


  25. QUENDT C, Ochs J, Hausser-Kinzel S, Hausler D, et al
    Proinflammatory CD20(+) T Cells are Differentially Affected by Multiple Sclerosis Therapeutics.
    Ann Neurol. 2021;90:834-839.
    PubMed     Abstract available


    October 2021
  26. MARAMATTOM BV, Krishnan P, Paul R, Padmanabhan S, et al
    Reply to 'Adenovirus COVID-19 vaccines and Guillain-Barre syndrome with facial paralysis by Dr Pegat et al.
    Ann Neurol. 2021 Oct 27. doi: 10.1002/ana.26257.
    PubMed    


  27. PEGAT A, Vogrig A, Khouri C, Masmoudi K, et al
    Adenovirus COVID-19 vaccines and Guillain-Barre syndrome with facial paralysis.
    Ann Neurol. 2021 Oct 26. doi: 10.1002/ana.26258.
    PubMed    


  28. TALLANTYRE EC, Vickaryous N, Anderson V, Asardag AN, et al
    COVID-19 vaccine response in people with multiple sclerosis.
    Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.
    PubMed     Abstract available


    September 2021
  29. KOCH MW, Kaur S, Sage K, Kim J, et al
    Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Sep 30. doi: 10.1002/ana.26239.
    PubMed     Abstract available


  30. OSOWICKI J, Morgan H, Harris A, Crawford NW, et al
    Guillain-Barre Syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines.
    Ann Neurol. 2021 Sep 15. doi: 10.1002/ana.26218.
    PubMed    


  31. ZUHORN F, Graf T, Klingebiel R, Schabitz WR, et al
    Postvaccinal Encephalitis after ChAdOx1 nCov-19.
    Ann Neurol. 2021;90:506-511.
    PubMed     Abstract available


    August 2021
  32. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
    Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
    Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
    PubMed     Abstract available


  33. PAN S, Chan JR
    Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
    Ann Neurol. 2021 Aug 17. doi: 10.1002/ana.26196.
    PubMed     Abstract available


  34. KOLB H, Absinta M, Beck ES, Ha SK, et al
    7T MRI Differetiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.
    PubMed     Abstract available


  35. TEWKESBURY G, Song JW, Perrone CM
    Magnetic Resonance Imaging of Autoimmune GFAP Astrocytopathy.
    Ann Neurol. 2021 Aug 13. doi: 10.1002/ana.26195.
    PubMed    


    July 2021
  36. HANDUNNETTHI L, Knezevic B, Kasela S, Burnham KL, et al
    Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26169.
    PubMed     Abstract available


  37. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
    MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
    PubMed     Abstract available


  38. GELIBTER S, Pisa M, Croese T, Finardi A, et al
    Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
    Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
    PubMed     Abstract available


  39. HAUSER SL
    Curing Multiple Sclerosis: How to Know When We're There?
    Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
    PubMed    


    June 2021
  40. ALLEN CM, Ramsamy S, Tarr AW, Tighe PJ, et al
    Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination.
    Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26144.
    PubMed     Abstract available


  41. MARAMMATOM BV, Krishnan P, Paul R, Padmanabhan S, et al
    Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine.
    Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26143.
    PubMed     Abstract available


  42. HARTUNG HP
    Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making.
    Ann Neurol. 2021;89:1084-1087.
    PubMed    


  43. WINGERCHUK DM, Fujihara K, Palace J, Berthele A, et al
    Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
    Ann Neurol. 2021;89:1088-1098.
    PubMed     Abstract available


    May 2021
  44. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
    Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
    Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
    PubMed     Abstract available


  45. BEUKER C, Wankner MC, Thomas C, Strecker JK, et al
    Characterization of extracranial giant cell arteritis with intracranial involvement and its rapidly progressive subtype.
    Ann Neurol. 2021 May 16. doi: 10.1002/ana.26101.
    PubMed    


  46. LANDA J, Guasp M, Miguez-Cabello F, Guimaraes J, et al
    Encephalitis with autoantibodies against the glutamate kainate receptors GluK2.
    Ann Neurol. 2021 May 5. doi: 10.1002/ana.26098.
    PubMed     Abstract available


  47. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    PubMed     Abstract available


    April 2021
  48. IZUKA S, Kobayashi T, Takahashi Y
    Tongue tremor in systemic lupus erythematosus.
    Ann Neurol. 2021 Apr 21. doi: 10.1002/ana.26088.
    PubMed    


  49. COX LM, Maghzi AH, Liu S, Tankou SK, et al
    The Gut Microbiome in Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
    PubMed     Abstract available


  50. MIRO O, Porta-Etessam J, Gonzalez Del Castillo J
    Reply to: "COVID-19 and the Risk of GBS".
    Ann Neurol. 2021;89:846-847.
    PubMed    


  51. PETZOLD A
    Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
    Ann Neurol. 2021;89:849-850.
    PubMed    


  52. WOSTYN P, Gibson CR, Mader TH
    Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
    Ann Neurol. 2021;89:849.
    PubMed    


  53. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    PubMed     Abstract available


    March 2021
  54. VANDEBERGH M, Andlauer TFM, Zhou Y, Mallants K, et al
    Genetic variation in WNT9B increases relapse hazard in multiple sclerosis.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26061.
    PubMed     Abstract available


  55. NOURBAKHSH B, Cordano C, Asteggiano C, Ruprecht K, et al
    Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062.
    PubMed     Abstract available


    February 2021
  56. DE MEO E, Bonacchi R, Moiola L, Colombo B, et al
    Early predictors of 9-year disability in pediatric multiple sclerosis.
    Ann Neurol. 2021 Feb 17. doi: 10.1002/ana.26052.
    PubMed     Abstract available


  57. DUBEY D, Kryzer T, Guo Y, Clarkson B, et al
    LUZP4 autoantibody: A novel germ cell tumor and paraneoplastic biomarker.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26050.
    PubMed     Abstract available


    January 2021
  58. SORMANI MP, De Rossi N, Schiavetti I, Carmisciano L, et al
    Disease modifying therapies and Covid-19 severity in Multiple Sclerosis.
    Ann Neurol. 2021 Jan 21. doi: 10.1002/ana.26028.
    PubMed     Abstract available


  59. KOAY S, Vichayanrat E, Bremner F, Panicker JN, et al
    Multi-modal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy.
    Ann Neurol. 2021 Jan 13. doi: 10.1002/ana.26018.
    PubMed     Abstract available


  60. DE BRUIJN MAAM, Bastiaansen AEM, Mojzisova H, van Sonderen A, et al
    The Antibodies Contributing to focal Epilepsy Signs and symptoms (ACES) score.
    Ann Neurol. 2021 Jan 11. doi: 10.1002/ana.26013.
    PubMed     Abstract available


  61. LEE ST, Lee BJ, Bae JY, Kim YS, et al
    CaV alpha2delta Autoimmune Encephalitis: A Novel Antibody and its Characteristics.
    Ann Neurol. 2021 Jan 7. doi: 10.1002/ana.26017.
    PubMed     Abstract available


  62. RINALDI S
    Coronavirus Disease 2019 and the Risk of Guillain-Barre Syndrome.
    Ann Neurol. 2021 Jan 4. doi: 10.1002/ana.26011.
    PubMed    


    December 2020
  63. FRAGIEL M, Miro O, Llorens P, Jimenez S, et al
    Incidence, clinical characteristics, risk factors and outcomes of Guillain-Barre syndrome in patients with Covid-19.
    Ann Neurol. 2020 Dec 9. doi: 10.1002/ana.25987.
    PubMed     Abstract available


    November 2020
  64. THAM M, Frischer JM, Weigand SD, Fitz-Gibbon PD, et al
    Iron heterogeneity in early active multiple sclerosis lesions.
    Ann Neurol. 2020 Nov 27. doi: 10.1002/ana.25974.
    PubMed     Abstract available


  65. FADDA G, Banwell B, Waters P, Marrie RA, et al
    Silent new brain MRI lesions in children with MOG-antibody associated disease.
    Ann Neurol. 2020 Nov 19. doi: 10.1002/ana.25957.
    PubMed     Abstract available


    October 2020
  66. SOTIRCHOS ES, Calabresi PA, Saidha S
    Reply to "Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?"
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25936.
    PubMed    


  67. CORDANO C, Yiu HH, Oertel FC, Gelfand JM, et al
    Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25933.
    PubMed    


  68. COMI G, Bar-Or A, Lassmann H, Uccelli A, et al
    The role of B cells in Multiple Sclerosis and related disorders.
    Ann Neurol. 2020 Oct 9. doi: 10.1002/ana.25927.
    PubMed     Abstract available


    September 2020
  69. VARLEY JA, Andersson M, Grant E, Berretta A, et al
    Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25908.
    PubMed     Abstract available


  70. CIOTTI JR, Grebenciucova E, Moss BP, Newsome SD, et al
    Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25907.
    PubMed    


  71. CARCELES-CORDON M, Mannara F, Aguilar E, Castellanos A, et al
    NMDAR Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice.
    Ann Neurol. 2020;88:603-613.
    PubMed     Abstract available


    August 2020
  72. PALMA JA, Gupta A, Sierra S, Gomes I, et al
    Autoantibodies blocking M3 muscarinic receptors cause postganglionic cholinergic dysautonomia.
    Ann Neurol. 2020 Aug 24. doi: 10.1002/ana.25882.
    PubMed     Abstract available


  73. MAGGI P, Sati P, Nair G, Cortese ICM, et al
    PARAMAGNETIC RIM LESIONS ARE SPECIFIC TO MULTIPLE SCLEROSIS: AN INTERNATIONAL MULTICENTER 3T MRI STUDY.
    Ann Neurol. 2020 Aug 15. doi: 10.1002/ana.25877.
    PubMed     Abstract available


  74. LANDA J, Gaig C, Planaguma J, Saiz A, et al
    Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration.
    Ann Neurol. 2020 Aug 2. doi: 10.1002/ana.25857.
    PubMed     Abstract available


  75. PETZOLD A, Coric D, Balk LJ, Hamann S, et al
    Longitudinal Development of Peripapillary Hyper-Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in Multiple Sclerosis.
    Ann Neurol. 2020;88:309-319.
    PubMed     Abstract available


    July 2020
  76. KHOURY SJ
    Progressive Multiple Sclerosis.
    Ann Neurol. 2020 Jul 6. doi: 10.1002/ana.25802.
    PubMed    


  77. KORALNIK IJ, Tyler KL
    COVID-19: A Global Threat to the Nervous System.
    Ann Neurol. 2020;88:1-11.
    PubMed     Abstract available


  78. KRYSKO KM, Graves JS, Rensel M, Weinstock-Guttman B, et al
    Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Ann Neurol. 2020;88:42-55.
    PubMed     Abstract available


    June 2020
  79. PETROVA N, Nutma E, Carassiti D, Newman J, et al
    Synaptic loss in the multiple sclerosis spinal cord.
    Ann Neurol. 2020 Jun 30. doi: 10.1002/ana.25835.
    PubMed     Abstract available


  80. RAUSCHENBERGER V, Wardenburg NV, Schaefer N, Ogino K, et al
    GlyR autoantibodies impair receptor function and induce motor dysfunction.
    Ann Neurol. 2020 Jun 26. doi: 10.1002/ana.25832.
    PubMed     Abstract available


  81. FILIPPI M, Preziosa P, Langdon D, Lassmann H, et al
    Identifying Progression In Multiple Sclerosis: New Perspectives.
    Ann Neurol. 2020 Jun 7. doi: 10.1002/ana.25808.
    PubMed     Abstract available


  82. LEBRUN-FRENAY C, Kantarci O, Siva A, Sormani MP, et al
    Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.
    Ann Neurol. 2020 Jun 4. doi: 10.1002/ana.25799.
    PubMed     Abstract available


    May 2020
  83. MAGLIOZZI R, Scalfari A, Pisani AI, Ziccardi S, et al
    The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.
    Ann Neurol. 2020 May 17. doi: 10.1002/ana.25786.
    PubMed     Abstract available


  84. AMOR S, Baker D, Khoury SJ, Schmierer K, et al
    SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
    Ann Neurol. 2020 May 8. doi: 10.1002/ana.25770.
    PubMed     Abstract available


  85. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    PubMed    


  86. LEE ST, Lim JA, Chu K, Lee SK, et al
    Reply to "Grading the severity of autoimmune encephalitis: When to evaluate?"
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25760.
    PubMed    


  87. CAI MT, Zheng Y, Zhang YX
    Grading the severity of autoimmune encephalitis: When to evaluate?
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25761.
    PubMed    


    April 2020
  88. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    PubMed    


  89. BARTELS F, Krohn S, Nikolaus M, Johannsen J, et al
    Clinical and MRI Outcome Predictors in Pediatric Anti-NMDA Receptor Encephalitis.
    Ann Neurol. 2020 Apr 21. doi: 10.1002/ana.25754.
    PubMed     Abstract available


  90. DESAI RA, Davies AL, Del Rossi N, Tachrount M, et al
    Nimodipine reduces dysfunction and demyelination in models of multiple sclerosis.
    Ann Neurol. 2020 Apr 15. doi: 10.1002/ana.25749.
    PubMed     Abstract available


  91. MAHAJAN KR, Nakamura K, Cohen JA, Trapp BD, et al
    Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25743.
    PubMed     Abstract available


  92. COLE JH, Raffel J, Friede T, Eshaghi A, et al
    Longitudinal assessment of multiple sclerosis with the brain-age paradigm.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25746.
    PubMed     Abstract available


  93. SOTIRCHOS ES, Caldito NG, Filippatou A, Fitzgerald KC, et al
    Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy.
    Ann Neurol. 2020 Apr 13. doi: 10.1002/ana.25738.
    PubMed     Abstract available


    March 2020
  94. RICHIE M, Pleasure S, Hurley J, Goss A, et al
    ANA Investigates: Pioneering Unbiased Diagnostics.
    Ann Neurol. 2020;87:327-328.
    PubMed    


    February 2020
  95. DALMAU J
    Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases.
    Ann Neurol. 2020;87:324-325.
    PubMed    


  96. JUREK B, Chayka M, Kreye J, Koelch M, et al
    Reply to "Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases".
    Ann Neurol. 2020;87:325-326.
    PubMed    


    November 2019
  97. PROBSTEL AK, Zamvil SS
    Do maternal anti-N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children?
    Ann Neurol. 2019;86:653-655.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: